Want to see ELTX full AI Analyst Report?
Elicio Therapeutics (ELTX) Ratios
Elicio Therapeutics Ratios
ELTX's free cash flow for Q2 2026 was $-8.16M. For the 2026 fiscal year, ELTX's free cash flow was increased by $0.00 and operating cash flow was $-8.16M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Mar 25 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 2.38 | 1.80 | 1.68 | 1.56 | 8.08 |
| Quick Ratio | 2.38 | 1.80 | 1.68 | 1.56 | 8.08 |
| Cash Ratio | 2.29 | 1.53 | 1.32 | 1.14 | 7.86 |
| Solvency Ratio | -1.59 | -1.28 | -2.16 | -1.97 | -1.71 |
| Operating Cash Flow Ratio | -4.56 | -3.22 | -3.35 | -3.23 | -2.12 |
| Short-Term Operating Cash Flow Coverage | 0.00 | -41.14 | 0.00 | -32.05 | -25.15 |
| Net Current Asset Value | $ -4.92M | $ -18.80M | $ 575.00K | $ -3.03M | $ 76.24M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.56 | 0.92 | 0.25 | 0.33 | 0.05 |
| Debt-to-Equity Ratio | 8.87 | -2.30 | 0.61 | 0.84 | 0.06 |
| Debt-to-Capital Ratio | 0.90 | 1.77 | 0.38 | 0.46 | 0.05 |
| Long-Term Debt-to-Capital Ratio | 0.85 | 2.30 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 15.81 | -2.49 | 2.39 | 2.54 | 1.18 |
| Debt Service Coverage Ratio | -32.93 | -37.07 | -31.13 | -5.49 | -28.40 |
| Interest Coverage Ratio | -33.29 | -98.87 | -33.75 | -6.60 | -44.85 |
| Debt to Market Cap | 0.08 | 0.34 | 0.00 | 0.04 | 0.05 |
| Interest Debt Per Share | 1.02 | 2.17 | 1.58 | 3.57 | 1.73 |
| Net Debt to EBITDA | 0.11 | -0.17 | 0.18 | 0.01 | 1.62 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 95.64% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | -186.23% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | -183.40% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -138.84% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -192.76% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -93.25% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | -192.76% |
| Net Income Per EBT | 100.00% | 100.00% | 100.00% | 100.00% | 48.38% |
| EBT Per EBIT | 104.92% | 115.36% | 98.46% | 118.86% | 138.84% |
| Return on Assets (ROA) | -153.01% | -184.18% | -129.65% | -124.46% | -27.35% |
| Return on Equity (ROE) | -2418.77% | 458.79% | -309.46% | -316.41% | -32.39% |
| Return on Capital Employed (ROCE) | -212.45% | -270.11% | -205.54% | -150.25% | -46.13% |
| Return on Invested Capital (ROIC) | -201.00% | -256.24% | -195.32% | -143.94% | -45.62% |
| Return on Tangible Assets | -153.01% | -184.18% | -129.65% | -124.46% | -27.35% |
| Earnings Yield | -32.46% | -83.39% | -83.46% | -154.49% | -140.07% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 35.13 |
| Payables Turnover | 1.68 | 1.13 | 0.27 | 0.38 | 0.26 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 6.38 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.29 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 4.42 |
| Cash Conversion Cycle | -217.45 | -321.62 | -1362.98 | -968.61 | -1382.76 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 10.39 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 217.45 | 321.62 | 1362.98 | 968.61 | 1393.15 |
| Operating Cycle | 0.00 | 0.00 | 0.00 | 0.00 | 10.39 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -2.41 | -3.04 | -6.47 | -7.15 | -7.48 |
| Free Cash Flow Per Share | -2.41 | -3.04 | -6.48 | -7.37 | -7.65 |
| Dividend Paid and CapEx Coverage Ratio | -2309.50 | -426.07 | -495.36 | -33.91 | -45.57 |
| Capital Expenditure Coverage Ratio | -2309.50 | -426.07 | -495.36 | -33.91 | -45.57 |
| Operating Cash Flow Coverage Ratio | -2.55 | -1.42 | -4.73 | -2.96 | -5.13 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | -0.85 |
| Free Cash Flow Yield | -30.33% | -59.70% | -77.69% | -125.05% | -129.80% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -3.09 | -1.20 | -1.20 | -0.65 | -0.71 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.67 |
| Price-to-Book (P/B) Ratio | 74.50 | -5.50 | 3.71 | 2.05 | 0.23 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.30 | -1.68 | -1.29 | -0.80 | -0.77 |
| Price-to-Operating Cash Flow Ratio | -3.30 | -1.68 | -1.29 | -0.82 | -0.79 |
| Price-to-Earnings Growth (PEG) Ratio | 0.08 | 0.03 | 0.05 | 0.01 | -0.00 |
| Enterprise Value Multiple | -3.16 | -1.41 | -1.10 | -0.76 | 1.26 |
| Enterprise Value | 117.84M | 70.66M | 36.19M | 17.94M | -65.25M |
| EV to EBITDA | -3.16 | -1.41 | -1.10 | -0.76 | 1.26 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | -2.30 |
| EV to Free Cash Flow | -3.19 | -1.90 | -1.10 | -0.79 | 2.67 |
| EV to Operating Cash Flow | -3.19 | -1.91 | -1.11 | -0.81 | 2.73 |
| Tangible Book Value Per Share | 0.11 | -0.93 | 2.25 | 2.88 | 25.47 |
| Shareholders’ Equity Per Share | 0.11 | -0.93 | 2.25 | 2.88 | 25.47 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 8.85 |
| Net Income Per Share | -2.58 | -4.25 | -6.96 | -9.10 | -8.25 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 1.00 | 0.48 |
| Interest Burden | 1.03 | 1.01 | 1.03 | 1.15 | 1.04 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 1.72 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Income Quality | 0.93 | 0.71 | 0.93 | 0.79 | 0.91 |
Currency in USD
